Intracranial tumor

The recurrence rate of intracranial tumors has been addressed in a number of large observational studies. Reports from the NCGS database (which includes 1262 children with brain tumors) and from England have shown no increase in intracranial tumor recurrence in patients treated with growth hormone (97,98). For patients with craniopharyngioma, postoperative irradiation reduced the recurrence rate, but growth hormone therapy did not increase the risk (99). 

M.J. Rudling, B. Angelin, C.O. Peterson and V.P. Collins, Low density lipoprotein receptor activity in human intracranial tumors and its relation to the cholesterol requirement, Cancer Res. 50... 

Lilge L, Portnoy M, Wilson BC. Apoptosis induced in vivo by photodynamic therapy in normal brain and intracranial tumor tissue. Br J Cancer 2000 83 1110-7. 

Patients with preexisting tumors or growth hormone deficiency secondary to an intracranial lesion should be examined routinely for progression or recurrence of the underlying disease process. In pediatric patients, clinical literature has revealed no relationship between somatropin replacement therapy and central nervous system (CNS) turmor recurrence or new extrracranial tumors. However, in childhood cancer survivors, an increased risk of a second neoplasm has been reported in patients treated with somatropin after their first neoplasm. Intracranial tumors, in particular meningiomas, in patients treated with radiation to the head for their first neoplasm, were the most common of these second neoplasms. In adults, it is unknown whether there is any relationship between somatropin replacement therapy and CNS tumor recurrence... 

Neoplasm has been reported in patients treated with somatropin after their first neoplasm. Intracranial tumors, in particular meingiomas, in patients treated with radiation to the head for their first neoplasm were the most common of these second neoplasms. In adults, it is unknown whether there is any relationship between somatropin replacement therapy and CNS tumor recurrence... 

Leukemia has ben reported in a small number of GHD patients treated with GH. It is uncertain whether this increased risk is related to the pathology of GH deficiency itself, GH therapy, or other associated treatments such as radiation therapy for intracranial tumors. On the basis of current evidence, experts cannot conclude that GH therapy is responsible for these occurrences. The risk to GHD, CRI, or Turner syndrome patients, if any, remains to be established... 

Intracranial tumor, e.g. glioma, meningioma Subdural hematoma Epileptic seizure... 

Of 378 patients with a clinical diagnosis of definite minor stroke, there were nine (2.4% 95% Cl, 1.3-4.5) with non-vascular pathology (six intracranial tumors, one demyelination, one arachnoid cyst, one subdural hematoma). Possible minor stroke was diagnosed in 36, and non-vascular pathology was identified in five (13.9% 95% Cl, 6.1-28.7), all of whom had intracranial tumors. 

A 2.7% ocular complication rate in 112 patients treated with a cumulative dose of carmustine 370 mg/m for intracranial tumors has been recorded (9). 

Elsas T, Watne K, Fostad K, Hager B. Ocular complications after intracarotid BCNU for intracranial tumors. Acta Ophthalmol (Copenh) 1989 67(l) 83-6. 

Vascular diseases, such as lupus Intracranial tumor... 

Krafft, C., Sobottka, S.B., Schackert, G. and Salzer, R. (2005) Near infrared Raman spectroscopic mapping of native brain tissue and intracranial tumors. Analyst, 130, 1070-7. 

Clear Cell Meningioma (WHO Grade II as an Intracranial Tumor)... 

Important characteristics of carcinoma as it relates to the CNS and meninges are its distinctively epithelial structure (Fig. 20.58A see Table 20.6) and the overwhelming predominance of metastatic over primary carcinomas. Metastatic carcinomas are described in detail in Chapter 8, Immunohistology of Metastatic Carcinomas of Unknown Primary. Rare primary brain carcinomas occur in the choroid plexus, from germ cell tumors of the pineal and suprasellar regions, and from cysts. 725 section emphasizes how to distinguish between carcinomas (see Fig. 20.58B to D) and various primary intracranial tumors (see Box 20.2). 

Spunberg JJ, Chang CH, Goldman M, et al Quality of long-term survival following irradiation for intracranial tumors in children under the age of two. Int J Radiat Oncol Biol Phys 7 727-736, 1981... 

Figure 5.29 Extravasation of particles from vessels in subcutaneous and intracranial tumors. Adapted from [30]. In panel a, tumors were implanted subcutaneously and in panel b, tumors were implanted intracranially. The bars indicate the range of particle sites between noticeable extravasation (lower limit) and no extravasation (upper limit). The pore size depends on the tumor type (shown on. v-axis) and the location of implantation.

PROACTII <6h 4< <30 but not comatose (except for isolated aphasia or hemianopia) No intracranial tumors, hemorrhage, significant mass effect with midline shift, or acute hypodense parenchymal lesion or effacement of cerebral sulci in >1/3 of the middle cerebral artery (MCA) territory UMI grade 1 of either the Ml segment or an M2 division of MCA... 

IMS I II <3 h (no lA infusion beyond 7 h) >10 No intracranial tumors, hemorrhage, significant mass effect with midline shift, or large (>l/3 of the MCA territory) regions of clear hypodensity on the baseline CT scan (sulcal effacement and/or loss of gray-white differentiation alone was allowed) Occlusion of the MCA, anterior cerebral artery. Posterior cerebral artery, or BA... 

---